Latest / Capital Ideas podcast
The heavy impact of weight loss drugs
Weight loss drugs that aim to radically curb appetites and prevent a host of obesity-related health problems are seeing unprecedented demand. At the same time, these drugs — sold under the brand names Ozempic, Wegovy and Zepbound — are raising questions for the food industry and companies that rely on cravings to sell their products. Capital Group portfolio manager Carl Kawaja shares his view on the heavy impact of weight loss drugs. #CapGroupGlobal
For full disclosures go to capitalgroup.com/global-disclosures
For our latest insights, practice management ideas and more, subscribe to Capital…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.